Abbreviated title: silent myocardial infarction in diabetes
Abstract Objective
Silent myocardial infarction (MI) is a prevalent finding in patients with type 2 diabetes and is associated with significant mortality and morbidity. Late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR) is the most validated technique for detection of silent MI but is time consuming, costly and requires administration of intravenous contrast. We therefore planned to develop a simple and low cost population screening tool to identify those at highest risk of silent MI validated against the CMR reference standard.
Methods

asymptomatic patients with type 2 diabetes underwent electrocardiogram (ECG),
echocardiography, biomarker assessment and CMR at 3.0T including assessment of left ventricular ejection fraction and LGE. Global longitudinal strain (GLS) from 2 and 4 chamber cines was measured using feature tracking.
Results
17
/100 patients with no history of cardiovascular disease had silent MI defined by LGE in an infarct pattern on CMR. Only 4 silent MI patients had Q waves on ECG. Patients with silent MI were older (65 vs 60, p=0.05), had lower E/A ratio (0.75 vs 0.89, p=0.004), lower GLS (-15.2% vs -17.7%, p=0.004) and higher NT-proBNP (106ng/L vs 52ng/L, p=0.003). A combined risk score derived from these 4 factors had an area under the receiver operating characteristic (ROC) curve of 0.823 (0.734-0.892), P<0.0001. A score of ≥2/5 had 82% sensitivity and 72% specificity for silent MI.
Conclusions
Using measures that can be derived in an outpatient clinic setting, we have developed a novel screening tool for the detection of silent MI in type 2 diabetes. The screening tool had significantly superior diagnostic accuracy than current ECG criteria for the detection of silent MI in asymptomatic patients. diabetes is reported to be between 21-28% (3, 4) . In these cohorts the presence of silent MI was strongly associated with an increase in major adverse cardiovascular events (MACE) and mortality.
Abbreviations
ACR
There has been a decrease in the rate of acute MI in patients with type 2 diabetes over the past two decades (6) . This reduction is thought to reflect improvements in glycaemic control and modification of other concomitant risk factors such as smoking, dyslipidaemia and blood pressure. However, per definition, silent MI is usually undetected and affected patients therefore fail to benefit from aggressive risk factor management, which may explain the poor clinical outcome in this group.
The detection of patients with silent MI remains a challenge as the most accurate method relies on CMR, which has limited availability, is relatively time consuming, costly and requires administration of intravenous contrast making it a less than ideal population screening tool. Several imaging and biomarker tests have been shown to be able to detect the presence and determine the extent of clinically recognised MI measured by LGE including Q waves on 12 lead electrocardiogram (ECG) (7), ejection fraction (8), strain parameters (9), high sensitivity troponin (hs-cTnT) (10) and aminoterminal pro-brain natriuretic peptide (NT-proBNP) (11) . However, the sensitivity and specificity of these tests to detect silent MI in type 2 diabetes is at present unknown.
In this study, we aimed to assess the diagnostic accuracy of several commonly measured parameters in asymptomatic patients with type 2 diabetes to detect silent MI. We hypothesised that a risk score derived from a combination of these measurements could accurately predict the presence of silent MI on CMR.
Methods
Enrolment Criteria
100 asymptomatic patients with type 2 diabetes were recruited from 30 primary care health centres in West Yorkshire, UK. The study was approved by the local ethical committee (13/YH/0098) and individuals were enrolled onto the study after informed consent. Exclusion criteria were known cardiovascular disease (including ischaemic heart disease, heart failure or persistent atrial fibrillation), kidney disease (eGFR <30), uncontrolled hypertension (with latest BP >140/80mmHg (12)), treatment with insulin or ACE inhibitor/angiotensin receptor blocker (to avoid patients with occult evidence of renal or other end organ damage).
CMR protocol
All patients underwent an identical CMR study on a dedicated cardiovascular 3 Tesla Philips Achieva TX system (Philips, Best, The Netherlands) equipped with a 32 channel coil and MultiTransmit® technology. Data were acquired during breath-holding at end expiration.
From scout CMR images, the left ventricular long and short axes were determined. Cine images covering the entire heart in the LV short axis plane and orthogonal long-axis planes were then acquired (balanced SSFP, spatial resolution 1.2x1.2x10mm³, 50 cardiac phases TR/TE 2.6/1.3ms, flip angle 40 o , field of view 300-420mm). Cines planned to cover the entire left atrium (LA) short axis plane in end systole were also acquired (as LV stack but slice thickness 5mm).
Late gadolinium enhancement (LGE) imaging was carried out more than 6 minutes after contrast injection (0.15mmol/Kg Gadovist, Bayer Schering) using inversion recovery-prepared T1-weighted echo. The optimal inversion time to null signal from normal myocardium was determined using a Look-Locker approach. Typical parameters are TR/TE 3.5/2.0 ms, flip angle 25 o , acquired spatial resolution 1.54x1.76x10mm 3 and performed in 10-12 short axis slices with further slices acquired in the vertical and horizontal long axis orientations, phase-swapped or imaged in systole, if indicated based on LGE imaging obtained or wall-motion abnormality.
CMR interpretation
CMR data were assessed quantitatively using commercially available software (CVI42 v5.1.0, Circle Cardiovascular Imaging Inc. Calgary, Canada) blinded to clinical details. LV mass, ejection fraction (EF) and LA volume were measured from short axis cine images.
For feature tracking analysis endocardial and epicardial LV contours were drawn on long axis 4 chamber and 2 chamber cines using a semi-automated process. Peak global longitudinal strain, systolic strain rate, early and late diastolic strain rates were measured. Late diastolic strain rates were defined as peak rate during active atrial contraction.
The presence of silent MI was identified by 2 physicians experienced (5 and 15 years) in CMR interpretation based upon typical subendocardial distribution of LGE present. The mass of LGE was quantified by the Otsu method (13).
Echocardiography, Electrocardiography and 24 hour Blood Pressure monitoring
All patients underwent echocardiography (Vivid e9, GE Medical Systems, Milwaukee, WI, USA)
focused on Doppler measurements of mitral inflow and tissue Doppler imaging (TDI) of the lateral and medial mitral annulus. E/A ratio (the inverse was used for the index), E', A' and S' are measured on the machine using inbuilt software. Diastolic dysfunction was graded 0-3 by an accredited echocardiographer blinded to clinical details according to international guidelines (14) . 12 lead electrocardiography (MAC500, GE Medical Systems, Milwaukee, WI, USA) was analysed by 2 physicians blinded to clinical details for the presence of Q waves according to international guidelines (15) . All patients underwent 24 hour blood pressure monitoring (6100, Welch-Allyn, Skaneateles Falls, NY, USA) set to inflate every 30 minutes in the day and every hour at night.
Blood tests
Blood was drawn from each subject at the time of CMR and tested for HbA1c. Serum was stored at -70°C and tested in one batch for hs-cTnT typical coefficient of variability 4.4% at 13.7ng/L and 3.6% 
Statistical analysis
Statistical analysis was performed using IBM SPSS® Statistics 22.0 (IBM Corp., Armonk, NY).
Continuous variables were expressed as means ± standard deviation and compared using t-test or
Mann Whitney U test depending on normality. Categorical variables were expressed as N (%) and compared using Fisher exact test.
Receiver operating characteristic (ROC) analysis was used to determine the diagnostic accuracy of parameters that had been significantly different in those with silent MI. The diagnostic accuracy is expressed as area under the curve (AUC) and 95% confidence interval. Optimal sensitivity and specificity were calculated using Youden index. Nested models were used to establish the best possible AUC from combining the variables associated with silent MI. AUCs were compared by using validated methods described by DeLong et al (16) .
Using the cut offs derived from the Youden analysis of the ROC curves each significant variable was given a binary classification (0 or 1). These four categorical variables were summed to calculate a silent MI risk score (range 0-5). The AUC of the silent MI risk score was compared to the best possible AUC from the individual parameters derived from the nested risk model.
We estimated that for a screening tool to be clinically useful it would need sensitivity >80% and to be significantly superior to the current screening test of Q waves which has a sensitivity of 28% (7).
Assuming that the prevalence of silent MI in a diabetic cohort to be around 10% (4) using a 2 sided
Fisher exact test with =0.05 and power 80% it was calculated 98 patients would be needed, including
Results
Seventeen of the 100 patients had evidence of silent MI defined as a subendocardial pattern of LGE identified by two experienced CMR reporters independently. Figure 1 shows Of the patient characteristics shown in Table 1 none had a significant association with quantitative mass of silent MI. Of the investigation findings shown in Table 1 the mass of silent MI only had significant correlations with LVEF (R=-0.81, P<0.0001), E/E' (R=-0.58, P0.02) and hs-cTnT (R=0.58, P=0.02).
Biomarkers
NT-proBNP was significantly higher in those with silent MI (105.8±132.2 vs 51.9±100.8ng/L, P=0.003). There was no difference in hs-CRP or hs-cTnT (P=0.57 and 0.42 respectively).
Development of a screening tool
The area under the ROC curve for age, Q waves, E/A ratio, GLS, and NT-proBNP are shown in Table   2 and Table   3 .
Discussion
The prevalence of silent MI (17%) detected by LGE imaging in this low risk asymptomatic population was high approaching 1 in 5 patients. We have found increasing age to be the only conventional risk factor associated with silent MI. We have identified several markers of silent MI that can be detected by cardiac imaging or blood test and have shown that these markers can be combined to develop a simple screening tool with good diagnostic accuracy.
We have demonstrated that a simple risk score can predict the presence of silent MI in patients with type 2 DM as shown by LGE on CMR. The risk score is composed of age, E/A ratio ≤ 0.79, GLS ≥ -18.4% and NT-proBNP > 29ng/L. These are all parameters that are often measured in a cardiology clinic or could easily be measured in community based screening. In the model we derived GLS from feature tracking of CMR cine images. However it is possible to measure GLS from standard echocardiography which has been demonstrated to show good agreement with GLS measured from CMR (17) .
The decision about where to make the cut off to recommend further investigation depends on whether sensitivity or specificity is the predominant clinical priority (Table 3) . If the cut off was set at a score ≥2 (100% sensitivity and 42% specificity) it would ensure that the vast majority of silent MI was detected with only 2.5 patients needing CMR to identify one patient with silent MI. Alternatively if the cut off was higher with a score ≥3 (82% sensitivity and 72% specificity) approximately 1 in 6 patients with silent MI would be missed but only 1.5 patients would need to be screened to detect one patient with silent MI. Either of these two scenarios are vastly superior to our current screening test using Q waves that only had 24% sensitivity in our asymptomatic cohort and 28% sensitivity in a cohort of patients with clinically recognised non-ST elevation MI (7).
All of the measured components within the score namely impaired GLS (18), elevated NT-proBNP (19) and E/A ratio (20) have been associated with adverse outcomes in patients with type 2 diabetes without prior history of MI. It is likely that a proportion of the mortality reported in these patients is due to silent MI. It has also been shown that larger infarcts have greater impairment of GLS (9), higher NT-proBNP (11) and altered mitral inflow (21) . Therefore all of the measured parameters have biological validity and prognostic significance that supports their inclusion in a risk score.
The imaging parameters associated with mass of silent MI were different from those included in the silent MI risk score and included LVEF, E/E' and hs-cTnT. These parameters are all recognised to correlate with extent of infarction and prognosis after symptomatic MI (8, 10, 22) . However, we have demonstrated that they were insensitive for the detection of silent MI in type 2 diabetes and of limited value in this setting.
It was an unexpected finding that conventional risk factors including fasting cholesterol, 24 hour BP, smoking and even previous glycaemic control had no association with the likelihood of silent MI in our population, although this may reflect a relatively small sample size and appropriate use of primary prevention medication. However, it is unclear whether the pathological processes that lead to silent MI are identical to acute MI. The lack of association with conventional risk factors suggests that further research is needed to identify alternative risk factors specifically for silent MI.
To our knowledge this is the first study to assess silent MI by LGE CMR in a truly asymptomatic diabetic population. Previous studies have demonstrated that in patients with diabetes, silent MI detected on CMR is associated with increased mortality and adverse cardiovascular events (3, 4 
Limitations
There a number of limitations to this work that should be acknowledged. First, we have excluded certain higher risk patients, for example those on insulin or ACE inhibitors and therefore general applicability of the findings is uncertain. The silent MI risk model we propose would need to be validated in more varied populations to broaden its clinical use. Second, we have not performed coronary angiography to confirm that silent MI was caused by coronary disease. However in an asymptomatic cohort undertaking an invasive procedure would not be appropriate. Third, we have recruited a relatively low proportion of women. However previous data suggest that the rate of silent MI tends to be equal or lower in women (3, 4) . Finally, the cut off points that we have used are based on Youden index which assigns equal importance to sensitivity and specificity. Depending on which of these is more important in clinical practice the thresholds would need to be altered accordingly. We have also assigned an equal score to each of the components which may oversimplify the complex nature of the disease process.
Conclusions
The rate of silent MI in this low risk asymptomatic cohort of patients with type 2 diabetes was higher than expected. No conventional risk factors other than age were associated with silent MI. Several simple clinical parameters including ECG Q waves, E/A ratio, GLS and NT-proBNP were associated with silent MI. By combining them we were able to define a novel screening tool with good diagnostic accuracy for the detection of silent MI which can be used both clinically and for interventional studies.
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